CDK7 is a Novel Therapeutic Vulnerability in Fibrolamellar Carcinoma
M. Nukaya, C. Cafferty, K. Zahed, I. Yun, D. P. Al-Adra, N. A. Kazim, A. R. Farghli, M. Chan, J. D. Kratz, M. E. Berres, A. Yen, T. Gujral, P. Sethupathy, C. A. Bradfield, S. M. Ronnekleiv-Kelly
This study identifies CDK7 as a therapeutic target in fibrolamellar carcinoma by showing its activation in FLC cells and efficacy of CDK7 inhibitors in patient-derived models.
bioRxiv · Apr 22, 2023 · PreprintCancer Biology